Wednesday, 01 July 2026
A Nottingham scientist has secured funding to bring a new technology to fruition that will identify early brain changes of Alzheimer’s disease, leading to earlier targeted treatments and prevent treatment progression.
Professor Stamatios Sotiropoulos from the 糖心原创’s School of Medicine has secured a 2026 Proof of Concept Grant from the European Research Council (ERC). This is one of the 182 Proof of Concept Grants across all disciplines in Europe and will give scientists the chance to explore the commercial or societal potential of their research fundings.
The new projects will delve into a diverse range of topics and will explore how frontier research can be translated into practical applications.
Neurodegenerative diseases, including Alzheimer’s disease (AD), pose a major global health and economic challenge, with over 10 million new cases annually and costs exceeding $1.3 trillion. As the first AD modifying therapies emerge, their effectiveness depends on identifying the right patients at the appropriate stage.
However, current diagnostic and clinical trial-support tools, such as PET scans and lumbar punctures, are costly, poorly scalable and have safety risks. This impairs patient stratification and trial efficiency, and delays diagnosis until significant neuronal loss has occurred, limiting treatment impact.
The team at Nottingham are developing a quantitative toolkit to enable early detection of AD-related brain changes, before irreversible clinical symptoms develop, allowing timely interventions that prevent disease progression.
Their platform transforms routine, widely accessible Magnetic Resonance Imaging (MRI) scans into personalised, population-referenced markers of brain health, building on over a decade of research in advanced brain MRI analytics.
Using AI-driven normative models, their approach supports better patient stratification, including selection of individuals likely to respond to therapy, so improving clinical trial outcomes, and enabling early diagnosis.
Professor of Computational Neuroimaging, Stamatios Sotiropoulos, said: “I am glad for this ERC Proof of Concept grant, which will allow us to explore commercialisation opportunities for our quantitative neuroimaging technologies, developed throughout the years with the support of the ERC."
In this project, we will explore efficacy of MRI for quantitatively characterising whole-brain changes caused by early neurodegenerative disease. We will leverage the power of modern AI architectures to learn from population-level MRI scans what are the typical ranges for healthy brain features. We will then apply these normative ranges to detect early pathology-induced abnormalities in scans of patients. The aim is to do so at early phases of mild cognitive decline and before irreversible symptoms develop, allowing timely interventions for dementia. We are fortunate to have clinical partners from the NUH NHS trust and pharmaceutical industry partners, who will feedback in validations and translations.鈥�
Dr Shaun Warrington, Senior Research Fellow in the School of Medicine and Co-Investigator, said: “It’s fantastic to see this ERC Proof of Concept grant funded. It is a great opportunity to move advanced MRI methods closer to clinical and trial use, enabling detection of meaningful brain changes early enough for intervention to make the greatest difference.”
Ekaterina Zaharieva, European Commissioner for Startups, Research and Innovation, said: “Many of today's innovations begin with a researcher asking a fundamental question. These 182 projects show that curiosity-driven science and real-world impact go hand in hand. With Proof of Concept funding, ERC researchers can test how their discoveries could become new treatments, technologies, services or solutions that benefit people across Europe.”
Story credits
More information is available from Professor Stamatios Sotiropoulos in the School of Medicine at Stamatios.Sotiropoulos@nottingham.ac.uk or
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.